Johnson & Johnson's $14.6 billion takeover of Intra-Cellular Therapies (ICT) earlier this year largely revolved around the potential for Caplyta in depression – and it has just scored FDA approval in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback